Literature DB >> 8158183

Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy.

.   

Abstract

A total of 151 patients on chronic treatment with amiodarone and other antiarrhythmic drugs were subjected to standard clinical and electrophysiological investigation to assess the prevalence and specificity of polyneuropathy. Twenty two untreated patients with cardiac disorders and 246 normal subjects served as controls. Abnormal electrophysiological findings supporting the diagnosis of polyneuropathy were present in 38 subjects (25%) given antiarrhythmic drugs, with even distribution among drugs, and four untreated patients (18%). Concurrent clinical abnormalities were present in five treated patients (one each with amiodarone, propafenone, and flecainide, and two with multiple drugs). Therefore, electrophysiological abnormalities are a common, although non-specific, feature in patients taking antiarrhythmic drugs. Amiodarone users do not seem at higher risk of polyneuropathy than subjects treated with other drugs or even untreated patients with cardiac disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158183      PMCID: PMC1072825          DOI: 10.1136/jnnp.57.3.340

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

1.  Amiodarone neuropathy (author's transl).

Authors:  H E Kaeser; J Ulrich; R Wüthrich
Journal:  Schweiz Rundsch Med Prax       Date:  1976-09-14

2.  Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy.

Authors:  S J Horwitz; F A Klipstein; R E Lovelace
Journal:  Lancet       Date:  1968-03-16       Impact factor: 79.321

3.  Perhexiline maleate induced lipidosis in human peripheral nerve and tissue culture: ultrastructural and biochemical changes.

Authors:  J J Hauw; J M Mussini; J M Boutry; R Escourolle; S Pollet; S Albouz; M L Harpin; N Baumann
Journal:  Clin Toxicol       Date:  1981-12       Impact factor: 4.467

Review 4.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

5.  Amiodaron neuropathy: further arguments for human drug-induced neurolipidosis.

Authors:  J F Lemaire; A Autret; K Biziere; J L Romet-Lemone; F Gray
Journal:  Eur Neurol       Date:  1982 Jan-Feb       Impact factor: 1.710

Review 6.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

7.  Neuromyopathy during chronic amiodarone treatment. A case report.

Authors:  C Meier; B Kauer; U Müller; H P Ludin
Journal:  J Neurol       Date:  1979-01-05       Impact factor: 4.849

8.  [Amiodaron neuropathy: clinical and pathological study of a new drug induced lipidosis (author's transl)].

Authors:  P Dudognon; J J Hauw; C de Baecque; J P Derrida; R Escourolle; E J Nick
Journal:  Rev Neurol (Paris)       Date:  1979 Jul-Aug       Impact factor: 2.607

9.  Amiodarone-induced experimental acute neuropathy in rats.

Authors:  L Santoro; F Barbieri; R Nucciotti; F Battaglia; F Crispi; M Ragno; P Greco; G Caruso
Journal:  Muscle Nerve       Date:  1992-07       Impact factor: 3.217

10.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

View more
  1 in total

Review 1.  [Clinical aspects of treatment with amiodarone].

Authors:  W Haverkamp; C Israel; A Parwani
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.